EmergingMed signs contracts with ILEX Oncology and Protein Design Labs



EmergingMed was founded to address the difficulties faced by the industry in patient recruitment, for clinical trials. According to EmergingMed, pharmaceutical and biotech companies experience patient recruitment delays in 80% of their FDA-mandated clinical trials and each day's delay per trial costs, on average, $1-2 million in lost revenues.

In addition, patients encounter problems in identifying trials that might be helpful for them and for which they may qualify. EmergingMed's patent-pending technology pre-qualifies and links patients to appropriate clinical trial investigators, by matching sponsors' trial criteria with the patients' disease profiles and geographical locations.

We believe that EmergingMed offers a new channel that is bringing clinical trials to the attention of more patients and their physicians than previous patient recruitment techniques, said Courtney Hudson, EmergingMed Founder and CEO. Besides our matching service, EmergingMed staff follow through on patient requests and connects the patient directly to the investigators of the trials patients wish to pursue. We expect to be the trusted source for patient-clinical trial matching, offering a broader spectrum of trials than other sites. We've addressed the major barriers that presently exist on both sides of the recruitment process.